Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02053376
Title A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Pittsburgh
Indications

biliary tract cancer

cholangiocarcinoma

Therapies

Regorafenib

Age Groups: adult
Covered Countries USA


No variant requirements are available.